Macrogenics Inc   (MGNX)
Other Ticker:  
Price: $17.2600 $0.45 2.677%
Day's High: $18.52 Week Perf: 1.29 %
Day's Low: $ 16.41 30 Day Perf: 30.56 %
Volume (M): 1,779 52 Wk High: $ 18.85
Volume (M$): $ 30,712 52 Wk Avg: $7.32
Open: $16.99 52 Wk Low: $4.29

 Market Capitalization (Millions $) 1,074
 Shares Outstanding (Millions) 62
 Employees 423
 Revenues (TTM) (Millions $) 121
 Net Income (TTM) (Millions $) 50
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 2

Macrogenics Inc
Macrogenics Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, with additional locations in Virginia and California. The company's mission is to discover and develop innovative therapeutics to address unmet needs in cancer and autoimmune diseases.

Macrogenics Inc. was founded in 2000 by Scott Koenig, who currently serves as the company's President and CEO. The company has since grown to employ approximately 300 people and has raised over $1 billion in funding.

Macrogenics Inc.'s proprietary technology platform is called Dual-Affinity Re-Targeting, or DART, which allows for the development of bi-specific antibodies that can target two different receptors simultaneously. The company's pipeline consists of several bi-specific antibodies in various stages of clinical development.

In oncology, Macrogenics Inc. is focused on developing bi-specific antibodies to target specific cancer cells and to engage and activate immune cells to combat the cancer. Their lead drug candidate in this area is margetuximab, a bi-specific antibody designed to target HER2-expressing breast cancer cells.

In autoimmune diseases, the company is developing bi-specific antibodies that target receptors involved in inflammatory and immune responses. Their lead drug candidate in this area is teplizumab, a bi-specific antibody designed to target T cells and modulate the immune response in type 1 diabetes.

Macrogenics Inc. has established partnerships with several pharmaceutical companies, including Eli Lilly, Incyte, and Janssen Biotech. These partnerships provide the company with additional funding and resources to advance their drug development programs.

In summary, Macrogenics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer and autoimmune diseases using its proprietary DART technology platform. The company has established partnerships with several pharmaceutical companies and has a pipeline of bi-specific antibodies in various stages of clinical development.

   Company Address: 9704 Medical Center Drive Rockville 20850 MD
   Company Phone Number: 251-5172   Stock Exchange / Ticker: NASDAQ MGNX
   MGNX is expected to report next financial results on March 07, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Macrogenics Inc

Macrogenics Inc. Faces Dire Fiscal Period as Revenue Plummets in Q3 2023

Financial News Report:
Macrogenics Inc. Announces Positive Earnings in Q3 2023, But Revenue Declines Sharply
For the third quarter of the 2023 earnings season, Macrogenics Inc. (NASDAQ: MGNX), a biopharmaceutical company specializing in antibody-based therapeutics for cancer treatment, reported positive earnings of $0.28 per share. This marks a significant improvement compared to the same period in the previous year when earnings per share were at -$0.40. However, it is important to note that there was a decline of -69.57% in earnings per share compared to the preceding reporting season, where earnings per share were $0.92.
The company also experienced a substantial drop in revenue, with a decrease of -75.087% to $10.40 million compared to $41.73 million in the same reporting season the previous year. Sequentially, revenue fell by -20.851% from $13.14 million. This decline in revenue could be a cause for concern and warrants further analysis.

Macrogenics Inc

Macrogenics Inc Bounces Back with Impressive Earnings in Challenging Quarter

Investors in the stock market have reasons to be excited about Macrogenics Inc (MGNX) and its recent performance. The company has managed to turn around its financials and achieve positive earnings per share (EPS) for the fiscal period ending June 30, 2023. With an EPS of $0.92 per share, this is a significant improvement from the previous year's EPS of -$0.67. Furthermore, the EPS has rebounded from -$0.61 per share in the preceding reporting period.
Although the revenue for MGNX has experienced a decline of -49.491% to $13.14 million compared to $26.01 million in the same period last year, investors should not be discouraged. It's important to note that revenue tumbled by -46.375% sequentially from $24.50 million. However, despite these declines, it is worth highlighting that the remainder of the Major Pharmaceutical Preparations sector has witnessed a 2.65% growth in revenue from the same reporting period last year, specifically in the second quarter of 2023. This demonstrates that MGNX's performance is not reflective of the wider market trend in its sector.

Macrogenics Inc

Macrogenics Inc. Smashes Expectations with Record-Breaking Revenue Growth in Q1's 2023 Earnings Season

Macrogenics Inc, a biopharmaceutical company, recently announced its financial results for the first quarter of 2023 earnings season. The report indicated a strong revenue growth of 120.665% year on year, reaching $24.50 million. However, the company continued to lose money, reporting an earnings per share of -$0.61.
Compared to the previous financial reporting period, the company's earnings per share fell sharply from $0.21 per share, and revenue tumbled by -66.489%, from $73.10 million. While this decrease may seem concerning, it's important to note that this specific reporting period encompasses a year that included significant changes due to the pandemic.


Macrogenics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com